Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11767 | 0.89 | MAPT (0.52) | MAPTHRH3 | |
| SCHEMBL11981474 | 0.89 | MAPT (0.56) | MAPTHRH3 | |
| SCHEMBL713789 | 0.89 | CARM1 (0.53) | — | |
| SCHEMBL25221689 | 0.87 | CARM1 (0.52) | — | |
| SCHEMBL17527074 | 0.85 | MAOA (0.52) | — | |
| SCHEMBL20989945 | 0.85 | CARM1 (0.55) | — | |
| SCHEMBL3666204 | 0.85 | MAPT (0.47) | MAPTHRH3 | |
| SCHEMBL8027241 | 0.85 | HDAC3 (0.50) | — | |
| SCHEMBL713894 | 0.85 | CARM1 (0.50) | — | |
| SCHEMBL4444675 | 0.84 | MAPT (0.43) | MAPTHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2014-02-20 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20080230743-A1 | Polyamine Derivative and Polyol Derivative | CIBA CORPORATION | 2008-09-25 | — | — | US | disclosed |
| EP-1840127-A1 | POLYAMINE DERIVATIVE AND POLYOL DERIVATIVE | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-10-03 | — | — | EP | disclosed |
| US-6949679-B1 | Polyamine transport inhibitors | UNIVERSITE LAVAL (CA) | 2005-09-27 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| WO-2000034226-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-06-15 | — | — | WO | disclosed |
| EP-1003715-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999054283-A1 | POLYAMINE TRANSPORT INHIBITORS | UNIVERSITE LAVAL (CA) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | MAPT 265/4885HRH3 1036/4885 |
| US-20080230743-A1 | Polyamine Derivative and Polyol Derivative | H1-0, H1-3, H1-2 | MAPT 1243/4885HRH3 62/4885 |
| US-20140051765-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | MAPT 3214/4885HRH3 2887/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | MAPT 3214/4885HRH3 2887/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | MAPT 3214/4885HRH3 2887/4885 |
| US-10350178-B2 | Methods and compositions for treatment of demyelinating diseases | PMP22, MAG, GMFG | MAPT 2061/4885HRH3 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.